stockportfolio.pro
Zenas BioPharma, Inc. (ZBIO)
Healthcare · Biotechnology · NasdaqGS
Zenas BioPharma, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $50.00M | $5.00M | $10.00M |
| Gross profit | — | — | — | — |
| Net income | $-119.28M | $-37.12M | $-156.99M | $-377.74M |
| Net margin | — | -74.2% | -3139.8% | -3777.4% |
Source: Zenas BioPharma, Inc. SEC filings (10-K).
Explore 4 years of Zenas BioPharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ZBIO in your portfolio →
Zenas BioPharma, Inc. financial history by metric
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Zenas BioPharma, Inc. — frequently asked questions
What is Zenas BioPharma, Inc.'s revenue?
Zenas BioPharma, Inc. (ZBIO) reported revenue of $10.00M for fiscal year 2025, up 100.0% from the prior year, according to its SEC filings.
Is Zenas BioPharma, Inc. profitable?
No — ZBIO reported a net loss of $-377.74M in fiscal 2025.
What is ZBIO's P/E ratio?
Zenas BioPharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Zenas BioPharma, Inc. have?
As of fiscal year 2025, ZBIO carried roughly $78.64M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Zenas BioPharma, Inc.'s market cap?
Zenas BioPharma, Inc. (ZBIO) has a market capitalization of about $1.13B, based on the latest data in our nightly-refreshed cache.
When does Zenas BioPharma, Inc.'s fiscal year end?
ZBIO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Zenas BioPharma, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.